These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31927213)

  • 1. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
    Qiu H; Jackson AL; Kilgore JE; Zhong Y; Chan LL; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2015 Mar; 6(9):6915-30. PubMed ID: 25762632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X; Wu H; Huang P; Zhang F
    J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
    Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
    Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Yao W; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JQ1, a selective inhibitor of BRD4, suppresses retinoblastoma cell growth by inducing cell cycle arrest and apoptosis.
    Zhang Y; Duan S; Jang A; Mao L; Liu X; Huang G
    Exp Eye Res; 2021 Jan; 202():108304. PubMed ID: 33080301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Polyhomeotic protein induces hyperplastic tissue overgrowth through the activation of the JAK/STAT pathway.
    González I; Simón R; Busturia A
    Cell Cycle; 2009 Dec; 8(24):4103-11. PubMed ID: 19923887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.